Invion Limited (IVX) is involved the global research and development of the Photosoft technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license and distribution rights to the Photosoft technology. Research and clinical trials are funded by the technology licensor, The Cho Group, via an R&D services agreement with the Company. The Group has operations in Australia and the United States with its wholly owned subsidiaries Invion Inc., Chronic Airway Therapeutics Limited and IVX Cosmetics Pty Ltd.
Invion
Follow
Get notifications in MyBN when activity occurs.
Company Activity
NEWS: Tagged in Aldoro goes nuts after niobium hits in Namibia | 06 Dec 2024 | |
NEW ROLE: T Chew, | 30 Oct 2023 | |
NEW ROLE: C Newton, Chief Executive Officer | 24 Nov 2020 | |
NEW ROLE: T Coogan, | 24 Nov 2020 | |
NEW ROLE: Melanie Leydin, Non-Executive Director | 03 Nov 2020 | |
NEW ROLE: Chiat T Chew, Chief Executive Officer, Executive Chairman, Executive Director | 03 Nov 2020 | |
NEW ROLE: Alan Yamashita, Non-Executive Director | 03 Nov 2020 | |
NEW ROLE: Rob Merriel, Non-Executive Director | 03 Nov 2020 | |
NEW ROLE: Alistair Bennallack, Non-Executive Director | 03 Nov 2020 |